Telomir Pharmaceuticals (NASDAQ:TELO) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models [Yahoo! Finance]
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line [Yahoo! Finance]
Telomir Pharmaceuticals (NASDAQ:TELO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.